Drugs / 6B11-OCIK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03542669 | Aug 2018 → Dec 2022 | ovarian carcinoma | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6B11-OCIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03542669 ↗ |
| Modality | Cell therapy | “6B11-OCIK, an adoptive cell therapy of autologous T cells induced by the humanized anti-idiotypic antibody 6B11 minibody plus dendritic cells and cytokines” PMID 34408750 ↗ Aug 2021 |
| Route | Intravenous | “after five cycles of intravenous infusion” PMID 34408750 ↗ Aug 2021 |